What they say:
A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Carbon monoxide-based therapy for pulmonary arterial hypertension: COR-M2 (CO (Carbon monoxide) Releasing Molecules-2) inhibits the development of pulmonary arterial hypertension via up regulation of its target gene Notch3
Significance of the study:
This study suggests, for the first time, that COR-M2 (CO (Carbon monoxide) Releasing Molecules-2), by increasing the expression of its target gene, it may decrease, in dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1). Thus, pharmacological formulations encompassing “COR-M2 or its analogues, either alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension (Figure 2). Together, By treating pulmonary hypertensive patients with Carbon monoxide (CO) or small molecule compounds that release CO, one may prevent pulmonary arterial hypertension.
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Undisclosed mechanistic information: How COR-M2 (CO (Carbon monoxide) Releasing Molecules-2) decreases the expression of Notch3 and its target gene
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at email@example.com
# Research cooperation
Web: http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Carbon monoxide-based therapy for pulmonary arterial hypertension: COR-M2 (CO (Carbon monoxide) Releasing Molecules-2) inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 7.34 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, drop us a line at firstname.lastname@example.org